

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	Pending
				Filing Date	Pending
				First Name Inventor	Rudolf Heller
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	20267 US2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	WIDMANN et al, Eur. J. Clinical Pharmacology 38(2) (1990) pgs. 143-146	
	C2	VON DER DOES et al, Eur. J. Clinical Pharmacology 38(2) (1990) pgs. 147-152	
	C3	MCTAVISH et al, Drugs 45(2) (1993) pgs. 232-258	
	C4	A. KLEEMANN et al., Pharmaceutically Active Substances; Syntheses, Patents, Uses, 2 nd Edition, Publisher: Georg Thieme, pp 469-470 (1982).	
	C5	BISTON P. et al. Acta Cardiologica, 49, pp. 145-155 (1994)	
	C6	RUDORF J.E. et al., Drugs, 36, Suppl 6, pp. 113-117 (1988)	
	C7	DUPONT A.G. et al., European Journal of Clinical Pharmacology, 38, Suppl 2, pp. S153-S157 (1990)	
	C8	WIDMANN L. et al., European Journal of Clinical Pharmacology, 38, Suppl 2, pp S143- S146 (1990)	
	C9	TOENNES, C.J. and McCurdy, V.E., Drug Development and Industrial Pharmacy, 15, pp. 165-185 (1989)	
	C10	Röhm Pharma Weiterstadt XP002145397 (1981)	
	C11	Derwent Abstract for DE 196 37 082	
Examiner Signature			DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.